| Symbol | INBX |
|---|---|
| Name | INHIBRX BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 11025 N. TORREY PINES ROAD,SUITE 140, CALIFORNIA, 92037, United States |
| Telephone | (858) 795-4220 |
| Fax | — |
| — | |
| Website | https://www.inhibrx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002007919 |
| Description | We are a clinical-stage biotechnology company dedicated to helping people with life-threatening conditions through scientific innovation and excellence. Additional info from NASDAQ: |
(10% Negative) INHIBRX BIOSCIENCES, INC. (INBX) Announces Delay in patients Trials for April 14 Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreInhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
Read moreDirector Vuori Kristiina MD 🟢 acquired 15.0K shares (1 derivative) of Inhibrx Biosciences, Inc. (INBX) at $95.22 ($1.4M) Transaction Date: Jun 03, 2026 | Filing ID: 000004
Read moreDirector Kayyem Jon Faiz 🟢 acquired 15.0K shares (1 derivative) of Inhibrx Biosciences, Inc. (INBX) at $95.22 ($1.4M) Transaction Date: Jun 03, 2026 | Filing ID: 000002
Read moreDirector FORSYTH DOUGLAS 🟢 acquired 15.0K shares (1 derivative) of Inhibrx Biosciences, Inc. (INBX) at $95.22 ($1.4M) Transaction Date: Jun 03, 2026 | Filing ID: 000002
Read moreDirector MANHARD KIMBERLY 🟢 acquired 15.0K shares (1 derivative) of Inhibrx Biosciences, Inc. (INBX) at $95.22 ($1.4M) Transaction Date: Jun 03, 2026 | Filing ID: 000002
Read more(99% Neutral) INHIBRX BIOSCIENCES, INC. (INBX) Announces Regulatory Update
Read moreNew Form SCHEDULE 13G/A - Inhibrx Biosciences, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000905148-26-002437 <b>Size:</b> 42 KB
Read more(90% Positive) INHIBRX BIOSCIENCES, INC. (INBX) Announces Enrollment Update for FOLFIRI Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06353997 | Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC P… | Phase2 | Triple Negative Breast Cancer | Recruiting | 2024-09-05 | 2029-06-01 | ClinicalTrials.gov |
| NCT06295731 | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC | Phase2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Active_Not_Recruiting | 2024-05-14 | 2029-05-01 | ClinicalTrials.gov |
| NCT04950075 | Study of INBRX-109 in Conventional Chondrosarcoma | Phase2 | Conventional Chondrosarcoma | Active_Not_Recruiting | 2021-09-23 | 2026-12-01 | ClinicalTrials.gov |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) … | Phase1 | Solid Tumor | Active_Not_Recruiting | 2019-12-10 | 2027-05-12 | ClinicalTrials.gov |
| NCT03815396 | Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha… | Phase1 | Alpha-1 Antitrypsin Deficiency | Completed | 2019-07-19 | 2022-08-18 | ClinicalTrials.gov |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumo… | Phase1 | Metastatic Solid Tumors | Terminated | 2019-01-30 | 2024-10-03 | ClinicalTrials.gov |
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Soli… | Phase1 | Ewing Sarcoma | Recruiting | 2018-10-08 | 2029-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Trifluridine + Tipiracil | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Bevacizumab | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Fluorouracil | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Leucovorin | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| pemetrexed | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| carboplatin | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Temozolomide | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Irinotecan | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| INBRX-109 | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Trifluridine + Tipiracil | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Bevacizumab | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Fluorouracil | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Leucovorin | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| pemetrexed | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| carboplatin | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Temozolomide | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Irinotecan | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| INBRX-109 | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Trifluridine + Tipiracil | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Bevacizumab | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Fluorouracil | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Leucovorin | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| pemetrexed | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| carboplatin | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Temozolomide | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Irinotecan | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| INBRX-109 | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Trifluridine + Tipiracil | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Bevacizumab | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Fluorouracil | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Leucovorin | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| pemetrexed | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| carboplatin | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Temozolomide | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Irinotecan | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| INBRX-109 | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Trifluridine + Tipiracil | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Bevacizumab | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Fluorouracil | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Leucovorin | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| pemetrexed | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| carboplatin | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Temozolomide | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Irinotecan | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| INBRX-109 | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-106 | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-106 | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-106 | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-106 | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-106 | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-101/rhAAT-Fc | Other | Phase PHASE1 | Alpha-1 Antitrypsin Deficiency | COMPLETED | NCT03815396 |
| Pembrolizumab | Other | Phase PHASE1 | Metastatic Solid Tumors | TERMINATED | NCT03809624 |
| INBRX-105 - PDL1x41BB antibody | Other | Phase PHASE1 | Metastatic Solid Tumors | TERMINATED | NCT03809624 |
| Nab paclitaxel 100mg/m2 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Paclitaxel 200mg/m2 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Cisplatin 75mg/m2 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Pemetrexed 500 mg/m2 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Carboplatin AUC-6 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Carboplatin AUC-5 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| pembrolizumab 400 mg | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| pembrolizumab 200 mg | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| INBRX-106 - Hexavalent OX40 agonist antibody | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Placebo | Other | Phase PHASE2 | Conventional Chondrosarcoma | ACTIVE_NOT_RECRUITING | NCT04950075 |
| INBRX-109 | Other | Phase PHASE2 | Conventional Chondrosarcoma | ACTIVE_NOT_RECRUITING | NCT04950075 |
| INBRX-106 | Other | Phase PHASE2 | Triple Negative Breast Cancer | RECRUITING | NCT06353997 |
| Pembrolizumab | Other | Phase PHASE2 | Triple Negative Breast Cancer | RECRUITING | NCT06353997 |
| Fluorouracil | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Leucovorin | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| pemetrexed | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| carboplatin | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Temozolomide | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Irinotecan | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| INBRX-109 | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-106 | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-106 | DRUG | Phase PHASE2 | Triple Negative Breast Cancer | RECRUITING | NCT06353997 |
| Placebo | DRUG | Phase PHASE2 | Conventional Chondrosarcoma | ACTIVE_NOT_RECRUITING | NCT04950075 |
| Nab paclitaxel 100mg/m2 | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Paclitaxel 200mg/m2 | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Cisplatin 75mg/m2 | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Pemetrexed 500 mg/m2 | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Carboplatin AUC-6 | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Carboplatin AUC-5 | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| pembrolizumab 400 mg | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| pembrolizumab 200 mg | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| INBRX-106 - Hexavalent OX40 agonist antibody | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| INBRX-101/rhAAT-Fc | DRUG | Phase PHASE1 | Alpha-1 Antitrypsin Deficiency | COMPLETED | NCT03815396 |
| Pembrolizumab | DRUG | Phase PHASE2 | Triple Negative Breast Cancer | RECRUITING | NCT06353997 |
| INBRX-105 - PDL1x41BB antibody | DRUG | Phase PHASE1 | Metastatic Solid Tumors | TERMINATED | NCT03809624 |
| Fluorouracil | DRUG | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Leucovorin | DRUG | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| pemetrexed | DRUG | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| carboplatin | DRUG | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Temozolomide | DRUG | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Irinotecan | DRUG | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| INBRX-109 | DRUG | Phase PHASE2 | Conventional Chondrosarcoma | ACTIVE_NOT_RECRUITING | NCT04950075 |